X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7350) 7350
male (4907) 4907
sirolimus - administration & dosage (4740) 4740
female (4383) 4383
middle aged (3257) 3257
animals (2709) 2709
treatment outcome (2600) 2600
sirolimus (2555) 2555
aged (2521) 2521
rapamycin (2499) 2499
sirolimus - analogs & derivatives (2434) 2434
cardiac & cardiovascular systems (2174) 2174
sirolimus - therapeutic use (1988) 1988
sirolimus - pharmacology (1963) 1963
everolimus (1858) 1858
drug-eluting stents (1809) 1809
immunosuppressive agents - administration & dosage (1773) 1773
adult (1606) 1606
stents (1601) 1601
transplantation (1569) 1569
time factors (1519) 1519
mice (1265) 1265
oncology (1237) 1237
surgery (1227) 1227
immunosuppressive agents - therapeutic use (1190) 1190
sirolimus - adverse effects (1154) 1154
stent (1109) 1109
coronary angiography (1056) 1056
follow-up studies (1017) 1017
mammalian target (1004) 1004
restenosis (956) 956
mtor (933) 933
risk factors (907) 907
thrombosis (905) 905
implantation (902) 902
paclitaxel - administration & dosage (881) 881
cardiovascular agents - administration & dosage (864) 864
prospective studies (844) 844
tor serine-threonine kinases - antagonists & inhibitors (843) 843
prosthesis design (834) 834
coronary artery disease - therapy (796) 796
analysis (795) 795
cancer (794) 794
care and treatment (786) 786
immunology (786) 786
pharmacology & pharmacy (781) 781
immunosuppressive agents - adverse effects (768) 768
rats (685) 685
retrospective studies (673) 673
coronary restenosis - prevention & control (667) 667
therapy (663) 663
research (657) 657
tor serine-threonine kinases - metabolism (651) 651
cyclosporine (636) 636
cardiovascular (635) 635
angioplasty (620) 620
immunosuppressive agents - pharmacology (620) 620
abridged index medicus (610) 610
drug therapy, combination (605) 605
tacrolimus (593) 593
kidney transplantation (578) 578
immunosuppression (576) 576
percutaneous coronary intervention (569) 569
angioplasty, balloon, coronary - instrumentation (556) 556
angioplasty, balloon, coronary - adverse effects (554) 554
trial (551) 551
dose-response relationship, drug (547) 547
signal transduction - drug effects (541) 541
efficacy (539) 539
cell line, tumor (534) 534
medicine & public health (516) 516
health aspects (510) 510
drug therapy (502) 502
disease models, animal (498) 498
angioplasty, balloon, coronary (492) 492
cell proliferation - drug effects (491) 491
aged, 80 and over (468) 468
inhibition (466) 466
cardiology (461) 461
graft rejection - prevention & control (458) 458
tor serine-threonine kinases (450) 450
drug delivery systems (449) 449
drug-eluting stent (449) 449
disease (447) 447
follow-up (443) 443
calcineurin inhibitors (436) 436
sirolimus - pharmacokinetics (435) 435
activation (433) 433
antineoplastic combined chemotherapy protocols - therapeutic use (432) 432
apoptosis (428) 428
cell biology (428) 428
coronary stenosis - therapy (423) 423
coronary restenosis - etiology (422) 422
risk assessment (420) 420
recipients (417) 417
drug-eluting stents - adverse effects (415) 415
phosphorylation (412) 412
outcomes (408) 408
drug administration schedule (401) 401
hematology (401) 401
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9192) 9192
Japanese (84) 84
Chinese (58) 58
French (58) 58
German (49) 49
Spanish (37) 37
Russian (14) 14
Portuguese (10) 10
Italian (9) 9
Polish (9) 9
Danish (5) 5
Hungarian (4) 4
Czech (2) 2
Lithuanian (2) 2
Croatian (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2007, Volume 357, Issue 25, pp. 2562 - 2575
This study examines the toxicity of immunosuppressive regimens in renal-transplant recipients. A regimen containing mycophenolate mofetil, daclizumab, low-dose... 
MULTICENTER TRIAL | MEDICINE, GENERAL & INTERNAL | CYCLOSPORINE MICROEMULSION | EFFICACY | KIDNEY-TRANSPLANTATION | IMMUNOSUPPRESSION | ALLOGRAFT RECIPIENTS | TACROLIMUS | MYCOPHENOLATE-MOFETIL | SIROLIMUS | NEPHROTOXICITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Enzyme Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized | Calcineurin Inhibitors | Treatment Failure | Adult | Diabetes Mellitus - etiology | Female | Drug Therapy, Combination | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Sirolimus - adverse effects | Tacrolimus - administration & dosage | Prednisone - administration & dosage | Glomerular Filtration Rate | Graft Rejection - prevention & control | Kaplan-Meier Estimate | Kidney Transplantation | Immunoglobulin G - administration & dosage | Opportunistic Infections | Sirolimus - administration & dosage | Mycophenolic Acid - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Cyclosporine - administration & dosage | Immunosuppressive Agents - adverse effects | Aged | Adrenal Cortex Hormones - administration & dosage | Transplantation | Corticosteroids | Kidneys | Research | Health aspects | Immunosuppressive agents | Medical research | Immunology | Inhibitor drugs | Transplants & implants | Toxicity | Inhibidors enzimàtics | Posologia | Ús terapèutic | Corticosteroides | Rebuig (Biologia) | Posology | Therapeutic use | Immunosupressive agents | Graft rejection | Trasplantament renal | Enzyme inhibitors | Adrenocortical hormones | Immunosupressors | Kidney transplantation | Tacrolimus: administration & dosage | Medical and Health Sciences | Graft Rejection: prevention & control | Immunoglobulin G: administration & dosage | Medicin och hälsovetenskap | Mycophenolic Acid: administration & dosage | Antibodies | Klinisk medicin | Monoclonal: administration & dosage | Prednisone: administration & dosage | Adrenal Cortex Hormones: administration & dosage | Immunosuppressive Agents: administration & dosage | Mycophenolic Acid: analogs & derivatives | Sirolimus: administration & dosage | Cyclosporine: administration & dosage | Calcineurin: antagonists & inhibitors | Diabetes Mellitus: etiology | Urologi och njurmedicin | Sirolimus: adverse effects | Adrenal Cortex Hormones: therapeutic use | Enzyme Inhibitors: administration & dosage | Immunosuppressive Agents: adverse effects | Clinical Medicine | Immunosuppressive Agents: therapeutic use | Urology and Nephrology
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2015, Volume 112, Issue 2, pp. E156 - E165
Current treatments to control pathological or unwanted immune responses often use broadly immunosuppressive drugs. New approaches to induce antigen-specific... 
Nanoparticles | Rapamycin | Anti-drug antibodies | Immune tolerance | Immunotherapy | THERAPEUTICS | anti-drug antibodies | IMMUNITY | TOLEROGENIC DENDRITIC CELLS | RISK-FACTORS | MULTIDISCIPLINARY SCIENCES | FACTOR-VIII | MECHANISMS | RESPONSES | immune tolerance | IMMUNOGENICITY | nanoparticles | UNRESPONSIVENESS | immunotherapy | rapamycin | Factor VIII - immunology | Oligodeoxyribonucleotides - administration & dosage | Nanoparticles - chemistry | Ovalbumin - immunology | Immunosuppression - methods | Nanocapsules - administration & dosage | Humans | Encephalomyelitis, Autoimmune, Experimental - immunology | Hypersensitivity, Delayed - immunology | Nanocapsules - chemistry | Peptides - administration & dosage | Antigens - administration & dosage | CD4-Positive T-Lymphocytes - immunology | Immunity, Humoral | Peptide Fragments - immunology | Proteins - administration & dosage | Female | Immunosuppressive Agents - administration & dosage | Disease Models, Animal | Lactic Acid - chemistry | Peptides - chemistry | Hemophilia A - immunology | Peptide Fragments - administration & dosage | Peptides - immunology | Immune Tolerance | Hemophilia A - therapy | Hypersensitivity, Delayed - therapy | Antigens - chemistry | Proteins - immunology | Encephalomyelitis, Autoimmune, Experimental - therapy | Sirolimus - administration & dosage | Animals | Ovalbumin - administration & dosage | Recombinant Proteins - immunology | Polyglycolic Acid - chemistry | Encephalomyelitis, Autoimmune, Experimental - prevention & control | Mice | Mice, Inbred BALB C | Nanoparticles - administration & dosage | Hemocyanins - administration & dosage | Proteins - chemistry | Antigens | Usage | Research | Health aspects | Immunological tolerance | Immunological research | Biological Sciences | PNAS Plus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | FC-GAMMA-RIIIA | PROGRESSION-FREE SURVIVAL | MULTICENTER PHASE-II | SQUAMOUS-CELL CARCINOMA | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | SUNITINIB MALATE SU11248 | CHRONIC MYELOID-LEUKEMIA | IMATINIB PLASMA-LEVELS | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 05/2015, Volume 45, Issue 5, pp. 408 - 410
Several 'lines of therapy' that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent... 
Chemo-gynecology | Molecular Dx | Gynecol-med | PEGYLATED LIPOSOMAL DOXORUBICIN | CARBOPLATIN | gynecol-med | BEVACIZUMAB | molecular Dx | COMBINATION | CHEMOTHERAPY | PACLITAXEL | PHASE-III TRIAL | THERAPY | ONCOLOGY | DOUBLE-BLIND | PROGRESSION | chemo-gynecology | Piperazines - administration & dosage | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Folic Acid - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Vinca Alkaloids - administration & dosage | Benzimidazoles - administration & dosage | Doxorubicin - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Antimetabolites, Antineoplastic - pharmacology | Female | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Everolimus | Ovarian Neoplasms - drug therapy | Recombinant Fusion Proteins - administration & dosage | Doxorubicin - administration & dosage | Sirolimus - analogs & derivatives | Folic Acid - analogs & derivatives | Phthalazines - administration & dosage | Pyrimidines - administration & dosage | Deoxycytidine - administration & dosage | Angiogenesis Inhibitors - pharmacology | Carboplatin - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors | Polyethylene Glycols - administration & dosage | Sirolimus - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Nivolumab | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Topotecan - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage
Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics
Journal Article
The Journal of Physiology, ISSN 0022-3751, 2009, Volume 587, Issue 7, pp. 1535 - 1546
Journal Article
Journal Article
Nature communications, ISSN 2041-1723, 2018, Volume 9, Issue 1, pp. 4098 - 13
Journal Article
Cancer Letters, ISSN 0304-3835, 2012, Volume 320, Issue 1, pp. 104 - 110
Abstract Molecularly targeted therapies have emerged as the leading theme in cancer therapeutics. Multi-cytotoxic drug regimens have been highly successful,... 
Hematology, Oncology and Palliative Medicine | Combination index | Dasatinib | Molecular targeted therapy | Rapamycin | ACTIVATION | SRC | BCR-ABL | TUMOR | MECHANISMS | SIMULATION | CHEMOTHERAPY | ONCOLOGY | RESISTANCE | SYSTEMS | KINASES | Niacinamide - analogs & derivatives | Paclitaxel - pharmacology | Nitriles - pharmacology | Humans | Epothilones - pharmacology | Thiazoles - administration & dosage | Chromones - administration & dosage | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Benzenesulfonates - pharmacology | Female | Chromones - pharmacology | Paclitaxel - administration & dosage | Butadienes - pharmacology | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | Pyrimidines - pharmacology | Breast Neoplasms - drug therapy | Sirolimus - pharmacology | Drug Synergism | Sirolimus - administration & dosage | Signal Transduction - drug effects | Butadienes - administration & dosage | Epothilones - administration & dosage | Tamoxifen - pharmacology | Cell Line, Tumor | Pyridines - pharmacology | Thiazoles - pharmacology | Care and treatment | Oncology, Experimental | Genes | Breast cancer | Research | Tamoxifen | Cancer | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2007, Volume 49, Issue 24, pp. 2312 - 2317
Journal Article